Disease relevance of TAG

• Tumor antigen induction by the envelope-defective Bryan strain of Rous sarcoma viruses [1].
• Tumor antigen-induced inhibition of leukocyte adherence was adapted and modified for use in glass test tubes for the study of cell-mediated antitumor immunity to human adenocarcinoma of the breast [2].
• Tumor antigen expression in melanoma varies according to antigen and stage [3].
• Tumor antigen P815AB is recognized by cytolytic T lymphocytes (CTL) on mouse mastocytoma P815 [4].
• Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease [5].

High impact information on TAG

• Tumor antigen and human chorionic gonadotropin in CaSki cells: a new epidermoid cervical cancer cell line [6].
• Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor [7].
• Corrigendum: Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells [8].
• Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery [9].
• Tumor antigen-specific CD4+ and CD8+ T lymphocytes, especially interferon-gamma (IFN-gamma)-producing type-1 helper T (Th1) and type-1 cytotoxic T (Tc1) cells, play a crucial role in tumor eradication [10].

Biological context of TAG

• Tumor antigen cross-presentation within draining lymph nodes (LNs) was then examined using Lyons-Parish analysis, detection of a proliferative response of 5,6-carboxyfluorescein diacetate succinimidyl ester-labeled CD8 T cells from T-cell receptor mice using flow cytometric analysis [11].
• Tumor antigen HuR binds specifically to one of five protein-binding segments in the 3'-untranslated region of the neurofibromin messenger RNA [12].
• CancerVax and the John Wayne Cancer Institute are co-developing Biotechnology Tumor antigen Canvaxin, a vaccine containing over 20 tumor antigens, for the potential treatment of melanoma and colon cancer [13].
• Tumor antigen phenotype, biologic staging, and prognosis in head and neck squamous carcinoma [14].

Anatomical context of TAG

• Tumor antigen-specific T helper cells in cancer immunity and immunotherapy [15].
• Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma [16].
• Tumor antigen might be either cross-presented to naïve cytotoxic T cells by professional antigen-presenting cells (pAPC), or presented directly by tumor cells that migrated to secondary lymphoid organs [17].
• Tumor-antigen 4. Its immunohistochemical distribution and tissue and serum concentrations in squamous cell carcinoma of the lung and esophagus [18].
• Tumor antigen incubated with lymphocytes from normal donors produced no increase in ARFC ability [19].

Regulatory relationships of TAG

• Tumor antigen-pulsed DCs effectively suppressed the growth of hepatocellular carcinoma in mice [20].

Other interactions of TAG

• Tumor-antigen 4 immunoreactivity was present in the cytoplasm of many SCC tissues, especially in the hyperparakeratotic region, and in the cytoplasm of differentiated squamous cells of the intermediate layer of normal epithelia of various organs, but not in those of other types of lung cancers or benign pulmonary diseases [18].
• Striking Immunodominance Hierarchy of Naturally Occurring CD8+ and CD4+ T Cell Responses to Tumor Antigen NY-ESO-1 [21].

Analytical, diagnostic and therapeutic context of TAG

• PURPOSE: Tumor antigen-loaded dendritic cells show promise for cancer immunotherapy [22].
• Tumor antigen loaded DC might potentially add therapeutic benefit with dendritic cell based vaccination [23].
• Tumor antigen NB/70K and CA 125 levels in the blood of preoperative ovarian cancer patients and controls: a preliminary report of the use of the NB12123 and CA 125 radioimmunoassays alone and in combination [24].

References